Alpine Woods Capital Investors’s Intellia Therapeutics NTLA Stock Holding History

Alpine Woods Capital Investors’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-10,000	Closed	-$134K	–	272
2019 Q3	$134K	Hold	10,000	–	–	0.02%	253
2019 Q2	$164K	Hold	10,000	–	–	0.03%	263
2019 Q1	$171K	Hold	10,000	–	–	0.04%	244
2018 Q4	$137K	Hold	10,000	–	–	0.03%	261
2018 Q3	$286K	Hold	10,000	–	–	0.06%	197
2018 Q2	$274K	Buy	+10,000	New	+$242K	0.06%	197

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Alpine Woods Capital Investors's NTLA Position: Q4 2019 in Review

Alpine Woods Capital Investors sold out of Intellia Therapeutics (NTLA) in Q4 2019, closing a stake of 10,000 shares — an estimated $134K sold.

Alpine Woods Capital Investors first reported a position in NTLA in Q2 2018 and held it in 6 quarters. The position peaked at $286K in Q3 2018. 143 funds tracked by Wall St. Rank hold NTLA as of Q4 2019.

Alpine Woods Capital Investors reported no remaining Intellia Therapeutics position as of Q4 2019 after selling out during the quarter.
Alpine Woods Capital Investors sold 10,000 Intellia Therapeutics shares in Q4 2019, an estimated $134K.
Alpine Woods Capital Investors first reported a position in Intellia Therapeutics in Q2 2018 and held it in 6 quarters.
Alpine Woods Capital Investors's Intellia Therapeutics position peaked at $286K in Q3 2018.
143 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2019.

Based on Alpine Woods Capital Investors's 13F filing for Q4 2019, filed 7 Feb 2020.